Invitation to Idorsia’s full year financial results 2020 webcast and conference call
Idorsia will publish its full year financial results 2020 on Thursday February 4, 2021, at…
Month: January 2021
OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
OSE is advancing an “Immunotherapy 2.0” future by leveraging MAbSilico’s artificial intelligence-powered software solutions and…
Biosenta Announces Note Financing
TORONTO, Jan. 28, 2021 (GLOBE NEWSWIRE) — Biosenta Inc. (“Biosenta” or the “Company”) listed on…
Marrone Bio Appoints Sue Cheung New Chief Financial Officer
DAVIS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII), an…
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
Clinical team led by neurological gene therapy expert, Dr. Krystof Bankiewicz, joins AskBio RESEARCH TRIANGLE…
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (NASDAQ:…
Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
– Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive…
Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in…
AGTC Announces Pricing of Public Offering of Common Stock and Warrants
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome
Webinar on Thursday, February 4, at 12:00 PM ET REDWOOD CITY, Calif., Jan. 28, 2021…
IceCure Announces a $15 Million Private Placement and Intention to Pursue NASDAQ Listing
Upon closing, the company to meet Nasdaq listing requirements without the need to effect a…
Alkahest Announces Peer-Reviewed Publication Demonstrating Safety and Tolerability of GRF6019 in Patients with Mild-to-Moderate Alzheimer’s Disease
GRF6019 was safe and well-tolerated, and patients experienced no cognitive decline and minimal functional decline…
COMPASS Pathways plc to participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference
George Goldsmith, Chairman & CEO, to deliver opening day keynote on 3 February London, UK,…
Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy
New hire helps lead Aquestive’s continued focus on its epinephrine program Provides update on Libervant™…
Avicanna Launches RHO Phyto™ Topical Gels in Canada and Initiates Clinical Studies
Deep Tissue Gel RHO Phyto Deep Tissue Gels RHO Phyto Deep Tissue Gels will be…
Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland
DENVER, Jan. 28, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE:…
Bavarian Nordic Reports Preliminary Financial Results for 2020
Revenue and EBITDA in line with guidance for 2020. Year-end cash position better than guided…
XORTX Announces Increase to Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY,…
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
WATERTOWN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company…
Cerevel Therapeutics Hosts Inaugural Virtual R&D Event to Review Darigabat (CVL-865) and Provide Overview of Key Preclinical Programs
Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric…